ONIVYDE (irinotecan liposome injection), for intravenous use, Initial U.S. Approval: 1996. Available In India.

ONIVYDE is a prescription medicine used to treat pancreatic cancer which has spread to other parts of the body (become metastatic). Brand Name "ONIVYDE (irinotecan liposome injection)" can be imported and made available on "Patient Name basis" treatment in India. If you have questions, please email IPN Support Team or Call Indian Pharma Network on +91 9891296838 (Mr. Tarun) / 9811747774 (Mr. Neeraj) for further details.

ONIVYDE (irinotecan liposome injection) is used for the treatment of patients with metastatic pancreatic cancer

What ONIVYDE (irinotecan liposome injection) is and What it is used for?

ONIVYDE is a topoisomerase inhibitor indicated, in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

How to buy ONIVYDE (irinotecan liposome injection) in India and overseas?

ONIVYDE (irinotecan liposome injection) suppliers in India. Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.

For procurement cost of ONIVYDE (irinotecan liposome injection) brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the ONIVYDE (irinotecan liposome injection) cost price in India.

The order for ONIVYDE (irinotecan liposome injection) will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

What irinotecan liposome is and What it is used for?

Irinotecan liposome injection is indicated for use in conjunction with fluorouracil and leucovorin as second-line therapy of metastatic pancreatic cancer that has progressed following gemcitabine-based therapy.

What are the brand names available for medicines containing irinotecan liposome?

ONIVYDE™ (irinotecan liposome injection), for intravenous use Initial U.S. Approval: 1996

Generic Name: irinotecan liposome

Dosage Forms And Strengths of ONIVYDE (irinotecan liposome injection).

Injection: 43 mg/10 mL single dose vial

GET IN TOUCH
with Indian Pharma Network

Indian Pharma Network, Delhi provides access to Onivyde (irinotecan liposome) on the Named Patient Import basis in India.

Indian Pharma Network

60/4 1st Floor, T&T Building, Indian Oil Complex,
Yusuf Sarai, New Delhi, Delhi 110016

Mobile / WhatsApp / Phone

M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398

Free Customer Support

info@indianpharmanetwork.co.in
urgent@indianpharmanetwork.co.in

ONIVYDE (irinotecan liposome injection) suppliers in India

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand ONIVYDE (irinotecan liposome injection) on prescription and Import License in Patient's Name only.

For overseas patients, ONIVYDE (irinotecan liposome injection) can be made available in Send your enquiry to find ONIVYDE (irinotecan liposome injection) in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.

News / Update for ONIVYDE (irinotecan liposome injection).

For ONIVYDE (irinotecan liposome injection) Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details

Arm Z1D of NCI-MATCH Shows Promise for Nivolumab Beyond Colorectal Cancer For More Details

Liposomal Irinotecan Active in Small Cell Lung Cancer